Weber Darin J. 4
Research Summary
AI-generated summary
ProKidney (PROK) CRO Darin Weber Receives 400,000-Share Award
What Happened Darin J. Weber, Chief Regulatory Officer of ProKidney Corp. (PROK), was granted a derivative award for 400,000 shares on March 1, 2026. The Form 4 shows the acquisition as an award/grant (transaction code A) with a reported price of $0.00 (no cash paid at grant). This is an equity compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: March 1, 2026; Form 4 filed March 3, 2026 (Accession: 0001193125-26-086728).
- Security: derivative award (option) for 400,000 shares; reported price $0.00.
- Vesting: vests in substantially equal monthly installments over four years beginning March 1, 2026 (footnote).
- Shares owned after the transaction: not specified in the filing.
- Filing timeliness: filed on March 3, 2026; filing does not indicate a late/untimely report.
Context This was an equity compensation grant (stock option award) intended as long-term incentive/retention; it is not an immediate purchase or sale. Because the award vests monthly over four years, the economic benefit to the insider depends on future vesting and any exercise terms or market price at exercise.